Colorectal carcinomas (CRC) are clinically challenging tumors. To identify novel predictive biomarkers of the therapeutic response, the OncoTrack
consortium recruited 106 CRC patients for establishing a biobank of organoids and xenografts models analysed by sequencing and tested in a pre-clinical platform. This unique resource generated a compendium of data for advancing our understanding of CRC. Linking molecular patterns with drug response profiles identified novel biomarkers, including a signature outperforming RAS/RAF mutations in predicting sensitivity to the EGFR inhibitor cetuximab.